real-time news and commentary for investors
Tuesday, Sep 3
Prana Biotechnology's Huntington's and Alzheimer's treatment touted as drug to watch by Elsevier Business Intelligence
- Prana Biotechnology (PRAN +9.5%) moves up after after Elsevier Business Intelligence touted its PBT2 drug candidate to treat Huntington's and Alzheimer's among the top 10 neuroscience projects to watch.
- The top 10 list is selected by an independent panel each year to highlight compounds addressing a large, unmet market, strong science and a diversity of indications.
- Other criteria include the potential for new opportunities beyond initial indications, multi-level partnering opportunities and a strong company behind the compound.
- PRAN is expected to release results on PBT2 in October 2013.